Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
RESEARCH TOOLSreports
Total Valuation
NewAmsterdam Pharma Company has a market cap or net worth of $1.80B. The enterprise value is $1.66B.
Market Cap$1.80B
Enterprise Value$1.66B
Share Statistics
NewAmsterdam Pharma Company has 109.82M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding109.82M
Owned by Insiders16.25%
Owned by Instutions63.79%
Financial Efficiency
NewAmsterdam Pharma Company’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -23.27%.
Return on Equity (ROE)-31.89%
Return on Assets (ROA)-27.94%
Return on Invested Capital (ROIC)-23.27%
Return on Capital Employed (ROCE)-23.27%
Revenue Per Employee$666,305.176
Profits Per Employee-$3,413,689.882
Employee Count68
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of NewAmsterdam Pharma Company is -10.04. NewAmsterdam Pharma Company’s PEG ratio is -0.53.
PE Ratio-10.04
PS Ratio53.22
PB Ratio3.20
Price to Fair Value3.20
Price to FCF-15.23
Price to Operating Cash Flow-15.29
PEG Ratio-0.53
Income Statement
In the last 12 months, NewAmsterdam Pharma Company had revenue of $45.31M and earned -$232.13M in profits. Earnings per share was -$2.52.
Revenue$45.31M
Gross Profit$45.29M
Operating Income-$168.09M
Pretax Income-$232.13M
Net Income-$232.13M
EBITDA-239.17M
Earnings Per Share (EPS)-2.52
Cash Flow
In the last 12 months, operating cash flow was -$151.09M and capital expenditures -$78.00K, giving a free cash flow of -$101.23M billion.
Operating Cash Flow-$151.09M
Free Cash Flow-$101.23M
Free Cash Flow per Share-$0.92
Dividends & Yields
NewAmsterdam Pharma Company pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-6.57%
Earnings Yield-9.96%
Stock Price Statistics
Beta1.81
52-Week Price Change-19.90%
50-Day Moving Average20.32
200-Day Moving Average20.00
Relative Strength Index (RSI)33.52
Average Volume (3m)1.36M
Important Dates
NewAmsterdam Pharma Company upcoming earnings date is May 7, 2025, Before Open.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
NewAmsterdam Pharma Company as a current ratio of 8.08, with Debt / Equity ratio of <0.01
Current Ratio8.08
Quick Ratio8.08
Debt to Market Cap<0.01
Net Debt to EBITDA3.19
Interest Coverage Ratio0.00
Taxes
In the past 12 months, NewAmsterdam Pharma Company has paid -$1.00K in taxes.
Income Tax-$1.00K
Effective Tax Rate<0.01%
Enterprise Valuation
NewAmsterdam Pharma Company EV to EBITDA ratio is -6.85, with an EV/FCF ratio of -10.39.
EV to Sales36.29
EV to EBITDA-6.85
EV to Free Cash Flow-10.39
EV to Operating Cash Flow-10.43
Balance Sheet
NewAmsterdam Pharma Company has $834.19M in cash and marketable securities with $448.00K in debt, giving a net cash position of -$833.74M billion.
Cash & Marketable Securities$834.19M
Total Debt$448.00K
Net Cash-$833.74M
Net Cash Per Share-$7.59
Tangible Book Value Per Share$8.02
Margins
Gross margin is 100.00%, with operating margin of -386.91%, and net profit margin of -530.25%.
Gross Margin100.00%
Operating Margin-386.91%
Pretax Margin-530.25%
Net Profit Margin-530.25%
EBITDA Margin-530.00%
EBIT Margin-530.25%
Analyst Forecast
The average price target for NewAmsterdam Pharma Company is $43.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$43.00
Price Target Upside167.75%
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast
EPS Growth Forecast